NeuroSense's PrimeC demonstrated statistically significant reduction in neuron-derived TDP-43 at 18 months alongside clinically meaningful slowing of ALS progression and extended survival in Phase 2b trials. These biomarker and functional outcomes support advancement to Phase 3 evaluation in a disease with limited therapeutic options and rapid neurodegeneration.
Key Points
- TDP-43 reduction sustained through 18 months with continuous treatment
- 36.5% slowing of ALSFRS-R decline at 12 months; 15-month median survival benefit
- No new safety signals observed; favorable tolerability profile maintained
Longevity Analysis
PrimeC targets a fundamental pathology in ALS—the accumulation of misfolded TDP-43 protein in neurons—addressing a mechanism that drives both neuronal death and progressive paralysis. The correlation between biomarker improvement and slowed functional decline suggests the intervention may interrupt the neurodegeneration cascade rather than merely masking symptoms. For individuals with ALS, whose disease typically progresses to respiratory failure within 3-5 years, a 15-month survival extension paired with maintained motor function represents a meaningful shift in disease trajectory. The Phase 3 pathway reflects regulatory recognition that this mechanism-based approach warrants larger-scale evaluation.
Original published by Longevity.Technology.